TMCnet News
Xcovery Collaborates with the National Cancer Institute and Children's Oncology Group for The NCI-COG Pediatric MATCH Clinical TrialXcovery, a developer of targeted therapeutics for cancer, today announced its participation in the National Cancer Institute (NCI) and Children's Oncology Group (COG) Pediatric MATCH clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) is a precision medicine cancer treatment clinical trial that will enroll children and adolescents with advanced cancers that have progressed on standard therapies. NCI is part of the National Institutes of Health. "Decades of research on the biology of cancer have revealed insights into the mechanisms that drive the disease, and that even with different cancers, they may share the same genomic alterations," said Lieming Ding, M.D., Chairman of Xcovery. "Our lead product, ensartinib, is a small molecule that inhibits anaplastic lymphoma kinase (ALK) and ROS1. We're excited to work with NCI and COG to provide ensartinib to the Pediatric MATCH study as a novel option to children with tumors harboring ALK or ROS1 genomic alternations, regardless of the tumor type." The NCI-COG Pediatric MATCH trial provides an opportunity to test targeted therapies in children and adolescents with advanced cancers who have few or no other treatment options. The study will attempt to demonstrate that matching certain drugs in children and adolescents whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of its type. DNA and RNA sequencing will be used to identify children whose tumors have a gentic abnormality for which an investigational targeted therapy exists. Pediatric MATCH is the first nationwide study of this type in the U.S., including over 200 COG member institutions and several pharmaceutical companies. "This trial would not have been possible without the enthusiastic support of the partnering pharmaceutical companies, as evidenced by their willingness to provide targeted agents for this trial," said NCI study co-chair Nita Seibel, M.D., of NCI's Division of Cancer Treatment and Diagnosis. "Some of the agents included have not previously been tested in children, so this trial will provide broader access to targeted agents for children and adolescents."
About NCI-COG Pediatric MATCH Study
About Ensartinib
About Xcovery
Forward-Looking Statements
View source version on businesswire.com: http://www.businesswire.com/news/home/20170724005762/en/ |